Poly (ADP-Ribose) Polymerase (PARP) Inhibitors to Reach $ 9.37 Billion by 2035

Poly (ADP-Ribose) polymerase (PARP) inhibitors market was valued at $4.0 billion in 2025 and is projected to reach $9.37 billion by 2035, growing at a CAGR of 8.8 % during the forecast period 2026-2035, according to a new report by Orion Market Research. The global poly (ADP-Ribose) polymerase (PARP) inhibitors market is driven by factors such as rising cancer prevalence, growing adoption of targeted therapies, and advancements in precision medicine. Among these ovarian cancer a major growth driver, with increasing demand for effective therapies and the shift toward earlier-stage treatment expanding the eligible patient population and market potential.

Browse the full report description of “Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Size, Share & Trends Analysis Report, By Drugs (Talazoparib, Veliparib, Olaparib, and Others), By Indication (Ovarian Cancer, Fallopian Tube Cancer, Breast Cancer, and Others), Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/poly-adp-ribose-polymerase-parp-inhibitors-market

Ovarian Cancer Prevalence Driving PARP Inhibitor Growth

The increasing prevalence of ovarian cancer globally remains a central driver of growth for the PARP inhibitors market. According to the World Ovarian Cancer Coalition, ovarian cancer is currently the 8th most common cancer among women and is projected to rise by over 55% to approximately 503,448 cases by 2050. This high mortality, along with the limitations of conventional therapies, has created strong demand for precision-targeted treatments such as PARP inhibitors.

This prevalence-driven market growth is further amplified by a significant clinical paradigm shift. Previously, PARP inhibitors were primarily used for late-stage or recurrent cases, limiting their patient pool. Today, they are increasingly employed as front-line maintenance therapy, positioning them as a standard-of-care option in earlier stages of the disease. Physicians are now more likely to prescribe these therapies immediately following initial surgery or chemotherapy, rather than waiting for recurrence, driving sustained adoption and expanding the market opportunity.

Based on these trends, the projected rise in ovarian cancer cases by 2050 could correspond to a substantial increase in the eligible patient population for PARP inhibitors, further reinforcing their role as a key growth driver in the global oncology therapeutics market.

Recent Key Developments

• In August 2025, Allarity Therapeutics, Inc. announced that the U.S. Food and Drug Administration had granted fast-track designation for its investigational PARP and WNT pathway inhibitor, stenoparib, for the treatment of advanced ovarian cancer.

• In January 2025, IMPACT Therapeutics’ PARP inhibitor Senaparib (IMP4297) got approval by China’s National Medical Products Administration (NMPA) for use as a first-line maintenance treatment in adult patients with advanced epithelial ovarian cancer, including fallopian tube and primary peritoneal cancers, following platinum-based chemotherapy.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
• Drugs
• Indication

Competitive Landscape – AstraZeneca, Cipla Ltd., Dr. Reddy’s Laboratories Ltd., GlaxoSmithKline and Pfizer Inc.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Report Segment

By Drugs

• Talazoparib
• Veliparib 
• Olaparib
• Others

By Indication

• Ovarian Cancer 
• Fallopian Tube Cancer 
• Breast Cancer
• Others

Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/poly-adp-ribose-polymerase-parp-inhibitors-market